Jan. 18 at 7:58 AM
JPM is behind us, who dominated the headlines:
Eli Lilly
$LLY Announced a massive
$1.X billion AI supercomputing partnership with Nvidia to slash drug discovery timelines. They also highlighted a shift toward genetic medicines for heart disease (Lp(a) targets).
Alpha Tau
$DRTS Stole the show with data from its Alpha DaRT® study, showing an 81% disease control rate in advanced pancreatic cancer. Investor focus is now on its five active U.S. clinical trials.
AbbVie
$ABBV Inked a
$5.6 billion licensing deal with RemeGen for a novel cancer antibody. This aggressive expansion signals AbbVie’s move to diversify beyond its traditional immunology stronghold.
ImmunityBio
$IBRX Reported a staggering 700% year-over-year revenue surge for its bladder cancer drug, ANKTIVA. With new global approvals and "holy grail" 53-month response data, it’s a top momentum play.
